Leerink Partners Reiterates Outperform Rating on Aurinia Pharmaceuticals (AUPH)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Leerink Partners Reiterates Outperform Rating on Aurinia Pharmaceuticals (AUPH)

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

June 30, 2025 6:00 AM EDT

Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins

Pharmacodynamic Effects Supportive of Once-Monthly Dosing

Plan to Initiate Clinical Studies in at Least Two Autoimmune Diseases in the Second Half of This Year

Aurinia to Host Conference Call Today, June 30, at 8:30 a.m. ET

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced positive results from a Phase 1 single-ascending-dose (SAD) study of aritinercept (AUR200), its dual inhibitor of B... More

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

June 29, 2025 5:00 PM EDT

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available... More